Interview: Why this biotech chose the ASX over the NASDAQ
FEAR & GREED | Business News
<p>Imagion Biosystems is a biotech company aiming to make a difference to the lives of cancer patients, with groundbreaking imaging techniques being trialled in Australian hospitals.</p>
<p>CEO Bob Proulx joins Sean Aylmer from San Diego to talk about Imagion's work, and why they chose to list on the ASX.</p>
<p><a href="https://fearandgreed.com.au" rel="nofollow">Find out more: https://fearandgreed.com.au</a></p>
<p>See <a href="https://omnystudio.com/listener" rel="nofollow">omnystudio.com/listener</a> for privacy information.</p>